Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Article Information
vol. 30 no. 4 138-150
Published By
Print ISSN
Online ISSN
History
- Published in print October 15, 2012.
Copyright & Usage
American Diabetes Association(R) Inc., 2012
Author Information
- Lisa S. Rotenstein, BA,
- Nina Ran, BA,
- Joseph P. Shivers, BA,
- Mark Yarchoan, MD and
- Kelly L. Close, MBA
Statistics from Altmetric.com
Article usage
In this Issue
October 2012, 30(4)
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Jump to section
- Article
- IN BRIEF
- Biosimilar Insulins: A Definition
- Biosimilars: Promise and Perceptions
- Biosimilar Manufacturing and Regulation
- Regulatory approval pathways for biosimilars
- Biosimilar Commercialization: Key Issues
- Clinical record
- Interchangeability with reference products
- Necessity of education
- Pricing issues
- Patient and provider experience
- Product labeling
- Reliability of manufacturing
- Distributor reputation and capabilities
- Biosimilar insulin coverage and utilization management
- Established Competition for Biosimilars: Brand Loyalty and Innovation
- Sanofi products
- Eli Lilly products
- Novo Nordisk products
- Conclusion
- ACKNOWLEDGMENTS
- Footnotes
- REFERENCES
- Info & Metrics